Covidien Trial Results Support New Treatment Approach For PAD - Quick Facts

(RTTNews) - Covidien (COV) Monday announced successful results from the study and trials demonstrating the safety and effectiveness of technologies used in the treatment of peripheral arterial disease.

The DURABILITY II three-year results support the use of a single long EverFlex self-expanding stent, while the DEFINITIVE AR acute 30-day data showed early success with the combined use of directional atherectomy and a drug-coated balloon in treating lower limb blockages in PAD patients.

In DURABILITY II, the use of the EverFlex stent demonstrated a low need for repeat procedures as well as a low rate of stent breakage. Stent fracture is a known cause of artery reblockage leading to repeat procedures.

In the DEFINITIVE AR randomized study, early results show that physicians are achieving better acute procedural success when treating patients with directional atherectomy plus anti-restenotic therapy versus using a drug-coated balloon alone.